Camp4 Therapeutics (CAMP) Common Equity (2023 - 2026)

Camp4 Therapeutics (CAMP) has 4 years of Common Equity data on file, last reported at $30.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 40.08% year-over-year to $30.9 million; the trailing twelve-month figure through Mar 2026 stood at $30.9 million (down 40.08% YoY), and the FY2025 full-year result was $47.7 million, down 24.45% from the prior year.
• Common Equity eased to $30.9 million in Q1 2026, from $47.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $63.1 million in Q4 2024 to a low of -$159.0 million in Q3 2024.
• A 4-year average of -$35.0 million and a median of $30.9 million in 2026 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 151.03% in 2024, while the deepest fall reached 42.51% in 2024.
• Tracing CAMP's Common Equity over 4 years: stood at -$123.7 million in 2023, then surged by 151.03% to $63.1 million in 2024, then slipped by 24.45% to $47.7 million in 2025, then tumbled by 35.22% to $30.9 million in 2026.
• Business Quant data shows CAMP's Common Equity at $30.9 million in Q1 2026, $47.7 million in Q4 2025, and $58.7 million in Q3 2025.